Fox Run Management L.L.C. Invests $813,000 in Harmony Biosciences Holdings, Inc. $HRMY

Fox Run Management L.L.C. acquired a new position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 21,738 shares of the company’s stock, valued at approximately $813,000.

Other institutional investors have also made changes to their positions in the company. EverSource Wealth Advisors LLC increased its stake in shares of Harmony Biosciences by 589.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 752 shares of the company’s stock worth $28,000 after purchasing an additional 643 shares during the period. Allworth Financial LP increased its stake in shares of Harmony Biosciences by 286.7% in the fourth quarter. Allworth Financial LP now owns 812 shares of the company’s stock worth $30,000 after purchasing an additional 602 shares during the period. Leonteq Securities AG bought a new position in shares of Harmony Biosciences in the fourth quarter worth about $30,000. National Bank of Canada FI bought a new position in shares of Harmony Biosciences in the third quarter worth about $40,000. Finally, Clearstead Advisors LLC increased its stake in Harmony Biosciences by 145.9% during the fourth quarter. Clearstead Advisors LLC now owns 1,178 shares of the company’s stock valued at $44,000 after acquiring an additional 699 shares during the period. 86.23% of the stock is currently owned by institutional investors.

Harmony Biosciences Trading Up 4.0%

Shares of HRMY opened at $35.48 on Thursday. Harmony Biosciences Holdings, Inc. has a 12-month low of $25.52 and a 12-month high of $40.87. The company has a quick ratio of 3.56, a current ratio of 3.58 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $2.05 billion, a price-to-earnings ratio of 14.31, a P/E/G ratio of 0.24 and a beta of 0.96. The stock’s 50-day moving average price is $30.58 and its 200 day moving average price is $33.12.

Harmony Biosciences (NASDAQ:HRMY) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.55 earnings per share for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.21). The company had revenue of $215.39 million for the quarter, compared to analyst estimates of $220.84 million. Harmony Biosciences had a net margin of 16.20% and a return on equity of 17.19%. The firm’s revenue for the quarter was up 16.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.78 earnings per share. As a group, research analysts predict that Harmony Biosciences Holdings, Inc. will post 3.2 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. HC Wainwright restated a “buy” rating on shares of Harmony Biosciences in a research note on Friday, May 22nd. Weiss Ratings lowered Harmony Biosciences from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, April 29th. Wall Street Zen lowered Harmony Biosciences from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Zacks Research upgraded Harmony Biosciences from a “strong sell” rating to a “hold” rating in a research note on Friday, May 1st. Finally, Needham & Company LLC lowered their price target on Harmony Biosciences from $46.00 to $44.00 and set a “buy” rating on the stock in a research note on Wednesday, February 25th. Four investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Harmony Biosciences presently has a consensus rating of “Hold” and an average target price of $40.89.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.